Robert T Dorr

  • 9048 Citations
  • 49 h-Index
1976 …2021
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Robert T Dorr is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 0 Similar Profiles
Doxorubicin Medicine & Life Sciences
Antineoplastic Agents Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Skin Medicine & Life Sciences
Mitomycin Medicine & Life Sciences
Pharmaceutical Preparations Medicine & Life Sciences
Pharmacokinetics Medicine & Life Sciences
Antidotes Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1978 2021

CANCER CENTER SUPPORT GRANT

Davis, T. P., Hersh, E. M., Weinstein, R. S., Miesfeld, R., Miller, T. P., Tsaprailis, G., Lynch, R., Chow, H., Nagle, R. B., Watts, G. S., Thomson, C., Roe, D., Stratton, S. P., Alberts, D. S., Hurley, L., Baker, A. F., Livingston, R. B., Dorr, R. T., Cress, A. E., Briehl, M. M., Mash, E. A., Duffy, J., Jones, S., Leibovitz, A., Meyskens, F., Moon, T., Trent, J., Newkirk, D., Von Hoff, D., Mount, D., Doetschman, T., Liebler, D., Marshall, J., McGovern, K., Grogan, T., Kraft, A., Powis, G., Peng, Y., Gerner, E., Aickin, M., Ritenbaugh, C., Taylor, C., Powell, M. B., Bowden, T., Taetle, R., Salmon, S., Ignatenko, N., Bhattacharyya, A. K., Futscher, B. W., Barton, J. K., Montfort, W. "., Roe, D., Garland, L. L., Doetschman, T. C., Kraft, A., Chow, H. & Ellis, N.

National Institutes of Health

9/1/786/30/21

Project: Research project

Neoplasms
Research
Pharmaceutical Services
Research Personnel
Clinical Trials
gemcitabine
Pancreatic Neoplasms
Oxidation-Reduction
Pharmaceutical Preparations
Metabolic Networks and Pathways

MEDICAL ONCOLOGY

Alberts, D. S., Hersh, E. M., Miller, T. P., Roe, D., Landowski, T. H., Dorr, R. T., Jones, S., Meyskens, F., Moon, T., Trent, J., Thomas, G., McGee, D., Durie, B. G., Dragovich, T., Gillies, R. J., Taylor, C., Dalton, W., Salmon, S. & Powis, G.

National Institutes of Health

6/1/788/31/13

Project: Research project

Neoplasms
Peptides
Pharmacokinetics
Biometry
Drug Resistance

Research Output 1976 2016

  • 9048 Citations
  • 49 h-Index
  • 236 Article
  • 3 Chapter
3 Citations (Scopus)

Magnetic resonance imaging identifies differential response to pro-oxidant chemotherapy in a xenograft model

Landowski, T. H., Guntle, G. P., Zhao, D., Jagadish, B., Mash, E. A., Dorr, R. T. & Raghunand, N., Jun 1 2016, In : Translational Oncology. 9, 3, p. 228-235 8 p.

Research output: Contribution to journalArticle

Heterografts
Reactive Oxygen Species
Magnetic Resonance Imaging
Drug Therapy
Neoplasms
16 Citations (Scopus)

Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors

Samulitis, B. K., Pond, K. W., Pond, E., Cress, A. E., Patel, H., Wisner, L., Patel, C., Dorr, R. T. & Landowski, T. H., 2015, In : Cancer biology & therapy. 16, 1, p. 43-51 9 p.

Research output: Contribution to journalArticle

gemcitabine
Histone Deacetylase Inhibitors
Pancreatic Neoplasms
Hypersensitivity
Phenotype
3 Citations (Scopus)

Synthesis and antitumor activity of heterocycles related to carbendazim

Remers, W. A., Iyengar, B. S., Dorr, R. T., Wisner, L. & Bates, R. B., 2015, In : Journal of Heterocyclic Chemistry. 52, 1, p. 136-141 6 p.

Research output: Contribution to journalArticle

Esters
Tumors
Triazines
Derivatives
Bearings (structural)
15 Citations (Scopus)

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma

Barr, P. M., Miller, T. P., Friedberg, J. W., Peterson, D. R., Baran, A. M., Herr, M., Perry, C. S., Cui, H., Roe, D., Persky, D. O., Casulo, C., Littleton, J., Schwartz, M., Puvvada, S. D., Landowski, T. H., Rimsza, L. M., Dorr, R. T., Fisher, R. I., Bernstein, S. H. & Briehl, M. M., Aug 21 2014, In : Blood. 124, 8, p. 1259-1265 7 p.

Research output: Contribution to journalArticle

B-Cell Lymphoma
Refractory materials
Non-Hodgkin's Lymphoma
Oxidation-Reduction
Cells
1 Citation (Scopus)

Characterization of a membrane-active anti-tumor agent, UA8967

Dorr, R. T., Samulitis, B. K., Wisner, L., Han, H., Zhao, Y., Beroza, P., Damodaran, K., Igarashi, S., Landowski, T. H. & Von Hoff, D. D., Jun 2013, In : Investigational New Drugs. 31, 3, p. 576-586 11 p.

Research output: Contribution to journalArticle

Membranes
Colonic Neoplasms
Neoplasms
Trypan Blue
Cell Membrane